Groselli S, Heinrich D, Lohmann C P, Maier M
Klinik und Poliklinik für Augenheilkunde, Klinkum rechts der Isar, Technischen Universität München, Ismaninger Str. 22, 81675, München, Deutschland.
Ophthalmologe. 2021 Feb;118(2):169-174. doi: 10.1007/s00347-020-01089-3.
The treatment options for patients with metastatic melanoma (MM) have been dramatically expanded in recent years with the approval of new drugs. The MEK (mitogen-acitvated protein kinase kinase) and BRAF (serine/threonine-protein kinase B-Raf coding gene) inhibitor combination therapy is currently part of the standard of care for stage IIIC/IV of BRAF mutant melanoma. The MEK inhibitor-associated retinopathy (MEKAR) is observed in patients with MM who are treated (or have been treated) with such a combination therapy. This article reports the case of a 72-year-old male patient, who suffered from such a pathological condition under treatment with binimetinib in combination with nivolumab. This case study illustrates the importance of interdisciplinary collaboration in the treatment of MM patients.
近年来，随着新药的获批，转移性黑色素瘤（MM）患者的治疗选择得到了极大的扩展。MEK（丝裂原活化蛋白激酶激酶）和BRAF（丝氨酸/苏氨酸蛋白激酶B-Raf编码基因）抑制剂联合疗法目前是BRAF突变型黑色素瘤IIIC/IV期标准治疗的一部分。接受过（或正在接受）这种联合疗法治疗的MM患者中观察到了MEK抑制剂相关视网膜病变（MEKAR）。本文报告了一名72岁男性患者的病例，该患者在接受比美替尼联合纳武利尤单抗治疗时出现了这种病理状况。本病例研究说明了跨学科协作在MM患者治疗中的重要性。
